Myocardial Infarction

Dr Roxana Mehran (Director of Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine, Mount Sinai Hospital, New York City, NY, USA) kindly shared her thoughts on the the PARADISE-MI trial (NCT02924727) from from the virtual ESC Congress 2021. Questions What has been the impact of angiotensin receptor-neprilysin inhibitors (ARNIs) on the treatment of […]

Prof. Gilles Montalescot (Professor, Pitié-Salpêtrière Hospital, Paris, France) kindly shared his thoughts on the difficulty of treating heart failure after acute myocardial infarction, the use of firibastat and the QUORUM clinical study (NCT03715998) from the virtual ESC Congress 2021. Questions Why does heart failure after acute myocardial infarction remain so challenging to treat? (0.19) Could […]

Prof. Marc A Pfeffer (Distinguished Dzau Professor of Medicine, Harvard Medical School, Boston, MA, US) kindly shared his highlights from Virtual ACC 2021. Speaker disclosures: Marc A Pfeffer has received consulting fees/honorarium from: Novo Nordisk, AstraZeneca Pharmaceuticals, DalCor, GlaxoSmithKline, Sanofi-Aventis, Boehringer Ingelheim-Lilly, Corvidia, Peerbridge, Novartis; Research/research grants from: Novartis; Other financial benefit: Novartis, DalCor Support: Interview […]

We were delighted to have the opportunity to speak with Prof. Marc A Pfeffer (Distinguished Dzau Professor of Medicine, Harvard Medical School, Boston, MA, US) to discuss the PARADISE-MI trial investigating sacubitril/valsartan vs. ramipril in a contemporary enriched AMI population, presented at ACC 2021. Abstract Title: Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in […]

Multivessel disease is common amongst patients presenting with ST-segment elevation myocardial infarction (STEMI). Previous studies have shown that up to 40–65% of patients presenting with STEMI have multivessel disease.¹ Pooled analyses of STEMI trials from the fibrinolytic and percutaneous coronary intervention (PCI) eras reveal that the presence of obstructive multivessel disease has been associated with […]

We caught up with Jose Gonzalez-Juanatey to discuss his highlights from this year’s meeting. Speaker disclosures: Jose Gonzalez-Juanatey has received research grants from: Boehringer-Ingelheim, Novartis, Bayer, AstraZeneca, and been a speaker or consultant to: Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daichii-Sankyo, Ferrer International, Novo Nordisk, Novartis, Pfizer, Sanofi, Servier. Support: Interview and filming supported […]

We were delighted to meet with Jose Gonzalez-Juanatey to discuss the REALITY clinical trial investigating one-year major cardiovascular events after restrictive Vs liberal blood transfusion strategy among patients with acute myocardial infarction and anemia: and the potential impact on future clinical practice. Questions: An overview of the REALITY clinical trial (00:06) What impact might these […]